Abiraterone Mylan Evrópusambandið - íslenska - EMA (European Medicines Agency)

abiraterone mylan

mylan ireland limited - abirateron asetat - blöðruhálskirtli - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Abiraterone Krka Evrópusambandið - íslenska - EMA (European Medicines Agency)

abiraterone krka

krka, d.d., novo mesto - abirateron asetat - blöðruhálskirtli - innkirtla meðferð - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Abiraterone Accord Evrópusambandið - íslenska - EMA (European Medicines Agency)

abiraterone accord

accord healthcare s.l.u. - abirateron asetat - blöðruhálskirtli - innkirtla meðferð - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Dimethyl fumarate Neuraxpharm Evrópusambandið - íslenska - EMA (European Medicines Agency)

dimethyl fumarate neuraxpharm

laboratorios lesvi s.l. - dímetýl fúmarat - heila-og mænusigg, köstum tilkynnt - Ónæmisbælandi lyf - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Dimethyl fumarate Mylan Evrópusambandið - íslenska - EMA (European Medicines Agency)

dimethyl fumarate mylan

mylan ireland limited - dímetýl fúmarat - heila-og mænusigg, köstum tilkynnt - Ónæmisbælandi lyf - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Dimethyl fumarate Teva Evrópusambandið - íslenska - EMA (European Medicines Agency)

dimethyl fumarate teva

teva gmbh - dímetýl fúmarat - multiple sclerosis, relapsing-remitting; multiple sclerosis - Ónæmisbælandi lyf - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Akeega Evrópusambandið - íslenska - EMA (European Medicines Agency)

akeega

janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - stækkun Æxli, gelding-Þola - Æxlishemjandi lyf - treatment of adult patients with prostate cancer.

Dimethyl fumarate Polpharma Evrópusambandið - íslenska - EMA (European Medicines Agency)

dimethyl fumarate polpharma

zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - dímetýl fúmarat - heila-og mænusigg, köstum tilkynnt - Ónæmisbælandi lyf - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Dimethyl fumarate Accord Evrópusambandið - íslenska - EMA (European Medicines Agency)

dimethyl fumarate accord

accord healthcare s.l.u. - dímetýl fúmarat - multiple sclerosis, relapsing-remitting; multiple sclerosis - Ónæmisbælandi lyf - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).